Trial Profile
Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2024
Price :
$35
*
At a glance
- Drugs Cyclophosphamide (Primary) ; Veliparib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- 21 Jul 2016 Planned primary completion date changed from 1 May 2017 to 1 Nov 2016.
- 21 Jul 2016 Status changed from recruiting to active, no longer recruiting.
- 18 Mar 2013 Planned number of patients changed from 72 to 92, as reported by ClinicalTrials.gov.